Innovation for Immunotherapy

Driving Breakthroughs in

Immune and Cell Therapy

for Solid Tumors

Hope for more patients

Pipeline

From discovery to clinical trials, our innovative pipeline is designed to push the boundaries of cancer immunotherapy. With a focus on novel targets and breakthrough approaches, we are pioneering new treatments for solid tumors.
Pipeline

Publications

Stay informed with the latest advancements in cancer immunotherapy. Explore scientific publications, clinical findings, and expert insights that shape the future of cell-based treatments.
Publications

News Center

Tcelltech Initiated China-US Registration Clinical Trial of Targeting B7-H3 CAR-T Cells in the Treatment of Grade 4 Glioblastoma

Read More

Tcelltech CAR-T Cell IND Approved for Brain Tumor Treatment

Read More

Tcelltech CAR-T Cells Approved by FDA

Read More

Tcelltech CAR-T Cell Therapy Recognized by FDA Orphan Drug (ODD)

Read More

Gangxiong Huang, MD

Co-founder, CEO

Dr. Huang’s research has focused on tumor metastasis and T-cell immunotherapy. He completed his postdoctoral training and subsequently served as a researcher at The University of Texas MD Anderson Cancer Center. He also served as a pathologist and Minjiang Scholar Professor at Fujian Medical University previously.

Lieping Chen, MD, PhD​

Co-founder, Scientific advisor

Dr. Chen is a pioneer in cancer immunotherapy. His research focuses on fundamental T-cell biology and the translation of scientific discoveries into clinical therapies, with a primary emphasis on cancer immunotherapy. He discovered PD-L1 and established its role in tumor immune evasion, laying the foundation for anti-PD-1/PD-L1 therapies that have transformed cancer treatment worldwide. Among his other numerous discoveries, B7-H3 has emerged as a promising universal therapeutic target for solid tumors. 

Dr. Chen is United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine at Yale University. He held faculty positions at the Mayo Clinic, Johns Hopkins University, and scientist positions in the Bristol-Myers Squibb Co. before joining Yale University. Dr. Chen is a member of the National Academy of Sciences, the National Academy of Medicine, and a Fellow of the American Association for Cancer Research.